The safety and tolerability of a single dose of intravitreally administered GEM103 (Gemini Therapeutics), a full-length recombinant CFH, is now being evaluated in the Phase 2a ReGAtta study in dry AMD (NCT04643886). This evidence concerns the gene CFH and dry age related macular degeneration.